Drug Trial Radar · NCT05108051
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
Last checked: Nov 19, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Nov 19, 2020
Primary completion
Mar 17, 2021
Study completion Mar 17, 2021
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.
Conditions
- Drug-drug Interaction
Interventions
ZSP1273Drug
ZSP1273 tablets 600mg administered orally once daily
OseltamivirDrug
Oseltamivir 75mg administered orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma pharmacokineticsTime frame: pre-dose and up to 72hours post-dose
- Plasma pharmacokineticsTime frame: pre-dose and up to 72hours post-dose
- Plasma pharmacokineticsTime frame: pre-dose and up to 72hours post-dose
- Plasma pharmacokineticsTime frame: pre-dose and up to 72hours post-dose
- Plasma pharmacokineticsTime frame: pre-dose and up to 72hours post-dose
- Number of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)Time frame: up to 37days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.